Cite
HARVARD Citation
D'Haens, G. et al. (n.d.). OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study. Journal of Crohn's and colitis. pp. i028-i029. [Online].